Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women
- PMID: 10188907
- PMCID: PMC2362699
- DOI: 10.1038/sj.bjc.6690249
Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women
Abstract
The relationship between expression of receptors for oestrogen and progesterone (ER and PR) and disease progression in breast cancer was investigated by comparing immunocytochemical determinations of ER and PR in fine needle aspirates from primary and secondary breast tumours. Rates of receptor expression were significantly higher in primary than in secondary lesions: for ER 63.3% (n = 689) compared with 45.3% (n = 223), and for PR 53.7% (n = 443) compared with 33.1% (n = 121). The effect of menopausal status was examined by subdividing the patient cohort into those over or under the age of 50 years. In both instances, ER expression in secondary tumours was relatively low; however, only postmenopausal patients had significantly lower rates of PR expression in secondary tumours. Consistent with this, an increase in the ER+PR- profile in secondary tumours compared with primary cases from postmenopausal patients was seen, and in a multivariate analysis, a specific absence of PR expression in secondary tumours was revealed. Comparison of ER and PR expression in simultaneously sampled primary tumours and lymph node metastases from the same patient showed that receptor expression was stable with progression to a metastatic site as results were concordant for ER in 92% (n = 88) and PR in 93.8% of cases (n = 65). These results suggest that absence of PR expression in primary breast cancer is associated with disease progression and may be a marker of an aggressive tumour phenotype.
Similar articles
-
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.Breast Cancer Res Treat. 2009 Jan;113(1):181-7. doi: 10.1007/s10549-008-9914-7. Epub 2008 Feb 9. Breast Cancer Res Treat. 2009. PMID: 18264760
-
Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.Breast Cancer Res Treat. 2005 May;91(1):81-7. doi: 10.1007/s10549-004-8235-8. Breast Cancer Res Treat. 2005. PMID: 15868434
-
Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.Anticancer Res. 1991 Sep-Oct;11(5):1701-6. Anticancer Res. 1991. PMID: 1768039
-
Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.Breast Cancer Res Treat. 2010 Oct;123(3):641-9. doi: 10.1007/s10549-010-1116-4. Epub 2010 Aug 15. Breast Cancer Res Treat. 2010. PMID: 20711809 Review.
-
[Drill biopsy and puncture biopsy for the determination of hormone receptors].Pathol Biol (Paris). 1983 Nov;31(9):755-60. Pathol Biol (Paris). 1983. PMID: 6361673 Review. French.
Cited by
-
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.Cancer. 2010 Mar 1;116(5):1234-42. doi: 10.1002/cncr.24816. Cancer. 2010. PMID: 20082448 Free PMC article.
-
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.Endocr Rev. 2008 Apr;29(2):217-33. doi: 10.1210/er.2006-0045. Epub 2008 Jan 23. Endocr Rev. 2008. PMID: 18216219 Free PMC article. Review.
-
Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.Breast Cancer Res Treat. 2010 Jan;119(1):71-85. doi: 10.1007/s10549-009-0334-0. Epub 2009 Feb 11. Breast Cancer Res Treat. 2010. PMID: 19205871 Free PMC article.
-
Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer.BMC Cancer. 2014 Mar 14;14:190. doi: 10.1186/1471-2407-14-190. BMC Cancer. 2014. PMID: 24629097 Free PMC article.
-
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores.BMC Med Res Methodol. 2021 May 22;21(1):108. doi: 10.1186/s12874-021-01297-8. BMC Med Res Methodol. 2021. PMID: 34022815 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials